Moreover, the authors examined a SuFEx-engineered PSMA-ligand based on PSMA-617 (Pluvicto) that showed enhanced LNCaP-tumor uptake as well as increased therapeutic efficacy. The gene discussed is FOLH1; the disease is neoplasm.